Clinical Trials Logo

Irritable Bowel Syndrome (IBS) clinical trials

View clinical trials related to Irritable Bowel Syndrome (IBS).

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06421922 Completed - Clinical trials for Irritable Bowel Syndrome-IBS

Effect of Different Dietary Therapies on Intestinal Barrier Integrity in Patients With Irritable Bowel Syndrome

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

This study aims to evaluate the effects of different dietary treatments on intestinal integrity in female subjects aged 19-50 years previously diagnosed with constipation-predominant irritable bowel syndrome (IBS). At the Gülhane Training and Research Hospital's gastroenterology clinic in Ankara, Turkey, a randomized controlled experiment was carried out. 60 individuals with IBS were randomly divided into three groups. Group 1 was assigned to a regular constipation diet, group 2 to a constipation diet rich in soluble fibers, and group 3 to a constipation diet with probiotic yogurt supplementation. Every individual was monitored for eight weeks. Plasma zonulin level was used to measure intestinal integrity both before and after treatment.

NCT ID: NCT05249023 Completed - Healthy Clinical Trials

Mode of Action of Butyrate in the Human Colon

Start date: April 11, 2018
Phase: N/A
Study type: Interventional

Butyrate has recently gained attention as an important microbial compound in human colon health. Several diseases, including Irritable Bowel Syndrome (IBS), have been linked with a loss of butyrate in the colon resulting in the hypothesis that butyrate is important for disease resistance. However, despite a plethora of preclinical evidence about butyrate's role in colon health, data from human studies are insufficient, largely due to the lack of available tools for colon-specific butyrate delivery and sampling. This project will elucidate butyrate's mode of action in the human colon and its implications for gut functioning in IBS and healthy participants by employing a unique in vivo human setting. Specifically, the regulatory capacity of butyrate on intestinal barrier function and the transcriptional host responses that are associated with an increase of butyrate in the colon will be determined. Moreover, butyrate's role as a signalling molecule for gut hormones and serotonin release will be studied.

NCT ID: NCT04462900 Completed - Clinical trials for Irritable Bowel Syndrome-IBS

Evaluate the Safety of Linaclotide in IBS-C Patients in China

Liberty
Start date: September 18, 2020
Phase:
Study type: Observational

This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for half year.

NCT ID: NCT03964103 Completed - Clinical trials for Irritable Bowel Syndrome (IBS)

qQ-lab Daily-IBS for Irritable Bowel Syndrome

Start date: October 4, 2016
Phase: N/A
Study type: Interventional

- Primary purpose: To assess satisfaction with overall improvement in symptoms, including individual bowel symptoms, after 4 weeks of administration of gQ-lab to patients with irritable bowel syndrome (IBS). - Secondary purposes: To assess the correlation between intestinal attachment and therapeutic effects of gQ-lab through the visual analog scale (VAS) assessment of each IBS-related symptom and measurement of changes in quality of life and fecal flora in the placebo group and gQ-lab group after 4 weeks of gQ-lab administration. To assess safety, including adverse reactions, vital signs (including weight), physical examination, and changes in blood test results. To examine the rate of positive gut quotient (gQ) values in patients diagnosed with IBS as per the ROME III criteria. Further, to examine how the ROME III-based symptom scale score compared with that of the quality of life scale in the gQ questionnaire.

NCT ID: NCT03550742 Completed - Clinical trials for Irritable Bowel Syndrome (IBS)

Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients

GRIPS
Start date: May 14, 2018
Phase: N/A
Study type: Interventional

This is an open labeled, one-armed real-world study in IBS-patients. All participants will receive active treatment for 12 weeks. The primary objective of the study is to assess the effect of Human Milk Oligosaccharides (HMOs) on bowel function in adults with IBS. Secondary objectives are to evaluate HMOs' tolerability, effect on participant reported satisfaction with bowel habits, interference with life in general, quality of life, somatic symptoms, and anxiety and depression in all patients and subgroups of patients.

NCT ID: NCT02955316 Completed - Clinical trials for Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China

IRONS
Start date: February 10, 2017
Phase:
Study type: Observational

The primary objective of this study is to estimate the overall prevalence of IBS medically diagnosed and diagnosed using Rome III or IV criteria in GI adult outpatients in China.

NCT ID: NCT02875847 Completed - Clinical trials for Irritable Bowel Syndrome (IBS)

Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The study is a randomised, placebo-controlled, double-blind parallel study in IBS patients. A total of 60 adult patients diagnosed with IBS-C, -D or -A/M according to Rome IV criteria will be included. The participants will be randomized into one of three groups consuming either HMO (two groups) or placebo (one group). The primary objective of the study is to establish the effect of HMOs on the faecal microbiota in IBS patients. Secondary objectives are to assess the effect on gastrointestinal symptoms, mucosal immunity, gut barrier function, quality of life, and anxiety and depression.

NCT ID: NCT02842281 Completed - Clinical trials for Irritable Bowel Syndrome (IBS)

Microbiome Fructan Metabolism and Symptoms in Childhood IBS

Start date: September 2014
Phase: N/A
Study type: Interventional

This study evaluates whether the gut microbiome is involved in determining whether children with irritable bowel syndrome (IBS) develop worsening GI symptoms (e.g. pain) when given fructans (a sugar often found in wheat). Participants will both receive a diet with fructans and a diet without fructans.

NCT ID: NCT02651532 Completed - Clinical trials for Irritable Bowel Syndrome (IBS)

Confocal Endomicroscopy Utility (p-CLE) in Irritable Bowel Syndrome

Start date: January 2016
Phase:
Study type: Observational

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. It has prevalence in general population of 5-20% and is more common in women and young adults. Despite being one of the most frequent reasons for consultation many patients are undiagnosed. There are no reliable biomarkers. The diagnosis is clinical, based on the Rome III criteria. IBS is characterized by chronic or recurrent abdominal pain associated with changes in bowel frequency and consistency, when other etiologies are excluded. The combination of the Rome III criteria with the absence of alarm symptoms have a sensitivity of 65%, specificity of 100%, 100% positive predictive value and negative predictive value of 76%. Current tests commonly fail to obtain an objective diagnosis, and effective therapies are lacking. There are no specific endoscopic findings that can discriminate IBS patients from healthy patients. Most colonoscopies are performed to rule out other etiologies and in more than 50% of the cases are normal.

NCT ID: NCT02113605 Completed - Clinical trials for Functional Dyspepsia

Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders

CBT
Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of the trial is to develop a treatment protocol to be used in trials studying internet-delivered CBT for children with functional gastrointestinal disorders (FGID). The study size is not based on power calculations but the estimated sample necessary to develop a treatment protocol. This study will include 20-30 children with FGID and their parents who will be treated individually (face-to-face). The treatment consists of 10 weekly sessions of exposure-based CBT. The study uses a pre- post-design with no control group.